The global contract research organization (CRO) services market is projected to grow from an estimated $93.02 billion in 2026 to $140.32 billion by 2031, a compound annual growth rate of 8.6 percent, according to a market report published this week.

The report attributes the growth to several converging forces reshaping how sponsors run clinical trials. A deepening cell and gene therapy pipeline is pushing sponsors toward CROs with specialized, complex-protocol expertise that many smaller biotechs cannot economically build in-house. Broader adoption of precision medicine is increasing the complexity of trial designs, requiring biomarker-driven patient stratification and more sophisticated site selection. And sponsors across the industry are increasingly seeking flexible, outsourced research capacity rather than fixed internal infrastructure, a preference that has only strengthened as sponsors look to diversify where and how they run trials amid shifting regulatory and trade conditions in their home markets.

That last dynamic has been a consistent tailwind for CRO markets outside the largest and most saturated jurisdictions. Sponsors weighing where to place early-phase and mid-stage studies increasingly factor in regulatory speed and total cost of trial execution alongside traditional considerations like patient population access. Australia’s clinical trial ecosystem has been a repeated beneficiary of this shift, combining the Clinical Trial Notification pathway, which allows many first-in-human studies to begin without waiting for a separate Therapeutic Goods Administration approval step, with a 43.5 percent research and development tax incentive available to eligible overseas sponsors running qualifying trials in the country. For sponsors weighing where to place capacity-constrained or cost-sensitive early studies, the combination has made Australian CRO and trial site networks a recurring part of the conversation, alongside more established options in North America and Europe.

Industry watchers expect the outsourcing trend to keep broadening beyond large pharma, historically the CRO industry’s core customer base, and further into small and mid-cap biotech, a segment that generally lacks the internal clinical operations infrastructure of larger sponsors and has become increasingly reliant on outsourced partners to run trials efficiently as venture funding remains selective about which programs get capitalized to Phase 3.

With cell and gene therapy programs alone expected to represent a growing share of total CRO-managed trial volume through the end of the decade, specialized therapeutic expertise, rather than simple headcount or geographic footprint, is increasingly what separates CROs winning share from those losing it.